UK Considers Reclassifying Ketamine as Class A Drug

The Home Office seeks expert advice on upgrading ketamine’s classification due to rising use and health risks.

Ketamine, currently a Class B drug in the UK, may be reclassified to Class A, which would increase penalties for possession and supply.
The Home Office cites record levels of ketamine use, with nearly 300,000 users aged 16-59 reported in 2023, as a key factor driving the review.
Health experts warn of severe health risks tied to chronic ketamine use, including bladder damage, kidney failure, and dependency.
Critics argue that previous reclassifications of drugs have not curbed usage and call for investment in mental health services and public health campaigns instead.
The drug’s rising popularity as a recreational and self-medication substance has shifted its use from clubs to everyday settings, raising concerns about dependency and misuse.